Short Form Disclosure

Information for Vermont Prescribers of Prescription Drugs CABOMETYX® (cabozantinib)

- This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.
- The prices listed below are Average Wholesale Prices ("AWP") as established and made available to the public by a third party publisher or as calculated from data made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
- The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed.

Price Comparison: Marketed product and lowest dosage of other products in the same therapeutic class*

Product Name	Unit Price
Marketed Products:	
CABOMETYX (20mg)	\$1,001.36
Other Products:	
AFINITOR (2.5mg)	\$675.74
AFINITOR DISPERZ (2mg)	\$672.36
INLYTA (1mg)	\$127.87
LENVIMA (8mg)	\$426.26
NEXAVAR (200mg)	\$240.70
OPDIVO (10mg/1ml)	\$359.71
SUNITINIB MALATE (SUN	\$218.26
PHARMACEUTICAL) (12.5mg)	
SUNITINIB MALATE (TEVA USA)	\$230.39
(12.5mg)	
SUNITINIB MALATE (MYLAN	\$218.02
PHARMACEUTICAL) (12.5mg)	
SUNITINIB MALATE (NORTHSTAR	\$217.47
RX) (12.5mg)	
SUNITINIB MALATE (DR. REDDY'S	\$218.02
LABORATORIES, INC) (12.5mg)	
SUTENT (12.5mg)	\$268.64
TORISEL (25mg/1ml)	\$2,330.47
VOTRIENT (200mg)	\$153.57

*Prices shown are the lowest dosage of each product. Prices for multi-source products have been averaged. Multiple forms of the same product (e.g. tabs and caps) have been considered one product, and the prices have been averaged.

Source: Redbook, January 2023

For additional price comparison information see: (link to Cabometyx VT Long Form Disclosure_Jan 2023)